Lexeo Therapeutics, Inc. Common Stock (LXEO) 10-Year Financial Performance & Capital Metrics

LXEO • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutLexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Show more

Revenue $0
EBITDA -$104M -55.6%
Net Income -$98M -48.1%
EPS (Diluted) -3.09 -24.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -85.37% +99.6%
ROIC -166.2%
Debt/Equity 0.08 -17.1%
Interest Coverage -927.77 -177.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 89 (top 11%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 19.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-21.21%

EPS CAGR

10Y-

5Y-

3Y-

TTM4.26%

ROCE

10Y Avg-57.92%

5Y Avg-57.92%

3Y Avg-69.85%

Latest-85.76%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	518.48K	1.66M	654K	0	0
Revenue Growth %	-	2.2%	-0.61%	-1%	-
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	518.48K	1.66M	654K	0	0
Gross Margin %	1%	1%	1%	-	-
Gross Profit Growth %	-	2.2%	-0.61%	-1%	-
Operating Expenses+	5.11M	52.29M	61.16M	68.51M	105.77M
OpEx % of Revenue	9.85%	31.56%	93.52%	-	-
Selling, General & Admin	787.5K	7.17M	12M	15.38M	31.68M
SG&A % of Revenue	1.52%	4.33%	18.35%	-	-
Research & Development	4.32M	45.12M	49.16M	53.13M	74.09M
R&D % of Revenue	8.33%	27.23%	75.17%	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-4.59M	-50.64M	-60.51M	-68.51M	-105.77M
Operating Margin %	-8.85%	-30.56%	-92.52%	-	-
Operating Income Growth %	-	-10.04%	-0.19%	-0.13%	-0.54%
EBITDA+	-4.59M	-50.62M	-59.36M	-66.67M	-103.76M
EBITDA Margin %	-8.85%	-30.55%	-90.77%	-	-
EBITDA Growth %	-	-10.03%	-0.17%	-0.12%	-0.56%
D&A (Non-Cash Add-back)	0	13K	1.15M	1.84M	2M
EBIT	-4.59M	-50.62M	-59.19M	-66.19M	-98.2M
Net Interest Income+	-147.15K	15K	1.23M	2.66M	7.44M
Interest Income	0	15K	1.32M	2.87M	7.56M
Interest Expense	147.15K	0	91K	205K	114K
Other Income/Expense	-565K	15K	1.23M	2.12M	7.43M
Pretax Income+	-5.15M	-50.62M	-59.28M	-66.39M	-98.33M
Pretax Margin %	-9.94%	-30.55%	-90.64%	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-5.15M	-50.62M	-59.28M	-66.39M	-98.33M
Net Margin %	-9.94%	-30.55%	-90.64%	-	-
Net Income Growth %	-	-8.82%	-0.17%	-0.12%	-0.48%
Net Income (Continuing)	-5.15M	-50.62M	-59.28M	-66.39M	-98.33M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.20	-2.01	-2.40	-2.49	-3.09
EPS Growth %	-	-9.05%	-0.19%	-0.04%	-0.24%
EPS (Basic)	-0.20	-2.01	-2.36	-2.49	-3.09
Diluted Shares Outstanding	25.17M	25.17M	25.17M	26.65M	31.79M
Basic Shares Outstanding	25.17M	25.17M	25.17M	26.65M	31.79M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	29.41M	136.68M	80.05M	124.29M	126.12M
Cash & Short-Term Investments	29.37M	135.86M	77.33M	121.47M	121.52M
Cash Only	29.37M	135.86M	77.33M	121.47M	35.01M
Short-Term Investments	0	0	0	0	86.5M
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	33.57K	696K	371K	3K	4.6M
Total Non-Current Assets+	2.5K	176K	21.26M	15.51M	20.82M
Property, Plant & Equipment	0	174K	13.78M	12.26M	10.56M
Fixed Asset Turnover	-	9.52x	0.05x	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	7.01M
Other Non-Current Assets	2.5K	2K	7.49M	3.25M	3.25M
Total Assets+	29.41M	136.86M	97.08M	139.81M	146.94M
Asset Turnover	0.02x	0.01x	0.01x	-	-
Asset Growth %	-	3.65%	-0.29%	0.44%	0.05%
Total Current Liabilities+	697.72K	7.45M	14.35M	17.24M	22.85M
Accounts Payable	44.32K	3.06M	2.68M	3.79M	6.42M
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	0	0	0	0	2.67M
Deferred Revenue (Current)	140.38K	46K	0	0	0
Other Current Liabilities	1.03K	961K	2.15M	3.36M	4.66M
Current Ratio	42.15x	18.35x	5.58x	7.21x	5.52x
Quick Ratio	42.15x	18.35x	5.58x	7.21x	5.52x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	34.25M	185.01M	195.68M	9.03M	7.25M
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	10.65M	9.03M	7.25M
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	34.25M	185.01M	185.03M	0	0
Total Liabilities	34.95M	192.46M	210.03M	26.27M	30.1M
Total Debt+	0	0	13.48M	11.64M	9.92M
Net Debt	-29.37M	-135.86M	-63.85M	-109.83M	-25.09M
Debt / Equity	-	-	-	0.10x	0.08x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-31.18x	-	-664.93x	-334.21x	-927.77x
Total Equity+	-5.54M	-55.6M	-112.95M	113.53M	116.84M
Equity Growth %	-	-9.04%	-1.03%	2.01%	0.03%
Book Value per Share	-0.22	-2.21	-4.49	4.26	3.68
Total Shareholders' Equity	-5.54M	-55.6M	-112.95M	113.53M	116.84M
Common Stock	1.6K	1.68K	0	3K	3K
Retained Earnings	-5.55M	-56.17M	-115.45M	-181.84M	-280.17M
Treasury Stock	0	0	0	0	-17K
Accumulated OCI	0	-185.01M	-185.03M	0	-103K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.13M	-44.18M	-54.56M	-59.5M	-81.15M
Operating CF Margin %	-6.04%	-26.66%	-83.43%	-	-
Operating CF Growth %	-	-13.1%	-0.23%	-0.09%	-0.36%
Net Income	-5.15M	-50.62M	-59.28M	-66.39M	-98.33M
Depreciation & Amortization	0	13K	1.15M	1.84M	2M
Stock-Based Compensation	0	386K	1.78M	3.04M	12.47M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	1.87M	0	0	530K	-23K
Working Capital Changes	150.15K	6.04M	1.79M	1.48M	2.73M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	44.32K	3.02M	-426K	-180K	2.38M
Cash from Investing+	0	-188K	-901K	-165K	-94.08M
Capital Expenditures	0	-188K	-672K	-115K	-481K
CapEx % of Revenue	-	0.11%	1.03%	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	-229K	-50K	0
Cash from Financing+	32.38M	150.86M	189K	103.79M	88.78M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	-223.59K	-203K	332K	-35K	491K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-3.13M	-44.37M	-55.46M	-59.66M	-81.63M
FCF Margin %	-6.04%	-26.78%	-84.8%	-	-
FCF Growth %	-	-13.16%	-0.25%	-0.08%	-0.37%
FCF per Share	-0.12	-1.76	-2.20	-2.24	-2.57
FCF Conversion (FCF/Net Income)	0.61x	0.87x	0.92x	0.90x	0.83x
Interest Paid	0	0	77K	176K	127K
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-22855.08%	-85.37%
Return on Invested Capital (ROIC)	-	-	-	-	-166.2%
Gross Margin	100%	100%	100%	-	-
Net Margin	-993.83%	-3055.04%	-9063.76%	-	-
Debt / Equity	-	-	-	0.10x	0.08x
Interest Coverage	-31.18x	-	-664.93x	-334.21x	-927.77x
FCF Conversion	0.61x	0.87x	0.92x	0.90x	0.83x
Revenue Growth	-	219.59%	-60.53%	-100%	-

Frequently Asked Questions

Growth & Financials

Lexeo Therapeutics, Inc. Common Stock (LXEO) grew revenue by 0.0% over the past year. Growth has been modest.

Lexeo Therapeutics, Inc. Common Stock (LXEO) reported a net loss of $105.0M for fiscal year 2024.

Dividend & Returns

Lexeo Therapeutics, Inc. Common Stock (LXEO) has a return on equity (ROE) of -85.4%. Negative ROE indicates the company is unprofitable.

Lexeo Therapeutics, Inc. Common Stock (LXEO) had negative free cash flow of $107.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener